UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

All anti-CD20 monoclonal antibodies have similar efficacy and risks: No

Multiple sclerosis, 2022-10, Vol.28 (12), p.1845-1846

2022

Volltextzugriff (PDF)

Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression

PloS one, 2013-03, Vol.8 (3), p.e57820-e57820

2013

Volltextzugriff (PDF)

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage

Multiple sclerosis, 2019-06, Vol.25 (7), p.937-946

2019

Volltextzugriff (PDF)

Extended interval dosing with ocrelizumab in multiple sclerosis

Multiple sclerosis, 2024-06, Vol.30 (7), p.847-856

2024

Volltextzugriff (PDF)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis

Journal of neuroinflammation, 2012-09, Vol.9 (1), p.215-215, Article 719

2012

Volltextzugriff (PDF)

Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression

PloS one, 2013, Vol.8 (3)

2013

Volltextzugriff (PDF)

CD11c+ B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy

Annals of clinical and translational neurology, 2024-04, Vol.11 (4), p.926-937

2024

Volltextzugriff (PDF)

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis

PloS one, 2015-03, Vol.10 (3), p.e0118830-e0118830

2015

Volltextzugriff (PDF)

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination

Neurology : neuroimmunology & neuroinflammation, 2016-02, Vol.3 (1), p.e191-e191

2016

Volltextzugriff (PDF)

Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis

Journal of neuroimmunology, 2023-08, Vol.381, p.578128-578128, Article 578128

2023

Volltextzugriff (PDF)

Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial

Neurology, 2014-04, Vol.82 (17), p.1499

2014

Volltextzugriff (PDF)

Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report

Multiple sclerosis, 2024-07, Vol.30 (8), p.1081-1083

2024

Volltextzugriff (PDF)

Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T cell subsets in multiple sclerosis

Clinical immunology (Orlando, Fla.), 2024-07, Vol.264, p.110262, Article 110262

2024

Volltextzugriff (PDF)

Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7 T MRI study

Brain (London, England : 1878), 2022-10, Vol.145 (10), p.3522-3535

2022

Volltextzugriff (PDF)

Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis

Frontiers in immunology, 2021-01, Vol.11, p.552101-552101

2021

Volltextzugriff (PDF)

Defining active progressive multiple sclerosis

Multiple sclerosis, 2017-11, Vol.23 (13), p.1727-1735

2017

Volltextzugriff (PDF)

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

Multiple sclerosis, 2017-04, Vol.23 (5), p.675-685

2017

Volltextzugriff (PDF)

Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study

Multiple sclerosis and related disorders, 2022-12, Vol.68, p.104246-104246, Article 104246

2022

Volltextzugriff (PDF)

GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis

Journal of autoimmunity, 2019-02, Vol.97, p.114-121

2019

Volltextzugriff (PDF)

Study protocol: effects of exercise booster sessions on preservation of exercise-induced adaptations in persons with multiple sclerosis, a multicentre randomised controlled trial-the MS BOOSTER trial

BMJ open, 2024-08, Vol.14 (8), p.e085241

2024

Volltextzugriff (PDF)

Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis

Multiple sclerosis and related disorders, 2021-07, Vol.52, p.102987-102987, Article 102987

2021

Volltextzugriff (PDF)

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

Multiple sclerosis, 2013-06, Vol.19 (7), p.877-884

2013

Volltextzugriff (PDF)

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis

PloS one, 2012-11, Vol.7 (11), p.e47578

2012

Volltextzugriff (PDF)

Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

Multiple sclerosis and related disorders, 2020-10, Vol.45, p.102391-102391, Article 102391

2020

Volltextzugriff (PDF)

Imaging cortical multiple sclerosis lesions with ultra-high field MRI

NeuroImage clinical, 2021-01, Vol.32, p.102847, Article 102847

2021

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(54)

Sprache

Englisch
(54)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

All anti-CD20 monoclonal antibodies have similar efficacy and risks: No

Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage

Extended interval dosing with ocrelizumab in multiple sclerosis

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis

Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression

CD11c+ B cells in relapsing–remitting multiple sclerosis and effects of anti‐CD20 therapy

Endogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination

Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis

Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial

Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report

Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T cell subsets in multiple sclerosis

Linking lesions in sensorimotor cortex to contralateral hand function in multiple sclerosis: a 7 T MRI study

Pregnancy-Induced Changes in microRNA Expression in Multiple Sclerosis

Defining active progressive multiple sclerosis

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study

GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis

Study protocol: effects of exercise booster sessions on preservation of exercise-induced adaptations in persons with multiple sclerosis, a multicentre randomised controlled trial-the MS BOOSTER trial

Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis

Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

Imaging cortical multiple sclerosis lesions with ultra-high field MRI

Suchergebnisse filtern